Clinical use of the co-formulation of insulin degludec and insulin aspart-Reference-Cited by-同舟云学术

Clinical use of the co-formulation of insulin degludec and insulin aspart

Published:2016-07-07 Issue:8 Volume:70 Page:657-667
ISSN:1368-5031
Container-title:International Journal of Clinical Practice
language:en
Short-container-title:Int J Clin Pract

Author:

Kumar A.¹,Awata T.²,Bain S. C.³,Ceriello A.⁴⁵,Fulcher G. R.⁶,Unnikrishnan A. G.⁷,Arechavaleta R.⁸,Gonzalez-Gálvez G.⁹,Hirose T.¹⁰,Home P. D.¹¹,Kaku K.¹²,Litwak L.¹³,Madsbad S.¹⁴,Pinget M.¹⁵,Mehta R.¹⁶,Mithal A.¹⁷,Tambascia M.¹⁸,Tibaldi J.¹⁹,Christiansen J.S.²⁰

Affiliation:

1. Diabetes Care & Research Centre; Patna India

2. Department of Diabetes, Endocrinology and Metabolism; International University of Health and Welfare Hospital; Tochigi Japan

3. Diabetes Research Unit Cymru; Swansea University & ABM University Health Board; Swansea UK

4. Insititut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM); Barcelona Spain

5. IRCCS MultiMedica; Milan Italy

6. University of Sydney; Royal North Shore Hospital; Sydney NSW Australia

7. Chellaram Diabetes Institute; Pune Maharashtra

8. Departamento de Endocrinologia; Universidad Autónoma de Guadalajara; Zapopan Mexico

9. Instituto Jalisciense de Investigación en Diabetes y Obesidad S.C. Guadalajara; Jalisco México

10. Division of Diabetes, Metabolism, and Endocrinology; Department of Medicine; Toho University School of Medicine; Tokyo Japan

11. Newcastle University; Newcastle upon Tyne UK

12. Department of Internal Medicine; Kawasaki Medical School; Kurashiki Japan

13. Endocrine, Metabolism and Nuclear Medicine Service; Diabetes Section; Hospital Italiano de Buenos Aires; Buenos Aires Argentina

14. Department of Endocrinology; Hvidovre Hospital; University of Copenhagen; Copenhagen Denmark

15. Department of Endocrinology; University of Strasbourg; Strasbourg France

16. Department of Endocrinology; National Institute of Medical Sciences and Nutrition; Salvador Zubirán; México City Mexico

17. Division of Endocrinology and Diabetes; Medanta the Medicity; Gurgaon Haryana India

18. Faculty of Medical Sciences; State University of Campinas; São Paulo Brazil

19. Queens Diabetes and Endocrinology Associates; Fresh Meadows; New York NY USA

20. Department of Clinical Medicine - The Department of Endocrinology and Diabetes; Aarhus University Hospital, NBG; Aarhus C Denmark

Funder

Novo Nordisk

Publisher

Hindawi Limited

Subject

General Medicine

Reference38 articles.

1. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes;Inzucchi;Diabetes Care,2015

2. Insulin therapy in people with type 2 diabetes: opportunities and challenges?;Home;Diabetes Care,2014

3. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people;Khunti;Diabetes Care,2013

4. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study;Peyrot;Diabet Med J Br Diabet Assoc,2012

5. Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial;Fulcher;Diabetes Care,2014

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of the effectiveness of long-acting insulin analogs in patients with type 2 diabetes mellitus;Journal of Public Health;2022-10-27

2. Pharmacokinetic Similarity between Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 and Originator Insulin Aspart Mix 70/30 (NovoMix 30) in Indian Adults with Type 2 Diabetes;Indian Journal of Endocrinology and Metabolism;2022-07

3. Efficacy and Safety of Insulin Degludec/Insulin Aspart (IDegAsp) in Type 2 Diabetes: Systematic Review and Meta-Analysis;Cureus;2022-06-02

5. Comparing time to intensification between insulin degludec/insulin aspart and insulin glargine: A single-center experience from India;Journal of Diabetology;2022